On March 19, 2025 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032 (Press release, Ipsen, MAR 19, 2025, View Source [SID1234651259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well received and largely oversubscribed by a diversified and solid institutional investor base.

"We are pleased with the outcome of this inaugural Rated Public Bond that reinforces and demonstrates investor’s confidence in Ipsen’s Investment Grade credit profile and long-term strategy," said Aymeric Le Chatelier, Executive Vice President and Chief Financial Officer, Ipsen. "While we remain committed to a disciplined financial approach, this issuance will further support our ambition to deliver ongoing sustained growth, driven by our internal pipeline and external innovation."

This transaction is an important component of Ipsen’s refinancing plan which included the successful renewal of €1,5 billion syndicated Revolving Credit Facility completed earlier this month for a period of 5 years with two possible extensions of one year each, significantly extending Ipsen’s debt maturity profile.